查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1465121

多重抗藥性結核病治療藥物市場：按產品、給藥方法和分銷管道 - 全球預測 2024-2030

Multidrug-resistant Tuberculosis Therapeutics Market by Offering (Medication, Therapies), Mode of Administration (Injectable Medications, Oral Medications), Distribution Channel - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年耐多藥結核病治療市場規模為2.81億美元，2024年達3.1132億美元，2030年達5.8862億美元，預計複合年成長率為11.14%。

多重抗藥性結核病（MDR-TB）治療是指對抗至少對兩種最有效的抗結核藥物異煙肼和利福平產生抗藥性的結核分枝桿菌所採用的治療策略和藥物。這些藥物是標準結核病治療的基石，對它們的抗藥性使治療過程顯著複雜化，因此需要使用替代藥物。多重抗藥性結核病治療通常需要較長的治療期，通常延長至 24 個月。此外，與用於治療藥物敏感結核病的第一線藥物相比，二線藥物更昂貴、效果較差且副作用風險更高。結核病發生率的上升，特別是在發展中國家，與有效多重抗藥性結核病治療的需求不斷增加直接相關。此外，世界各地政府和非政府組織不斷增加的財政援助、宣傳宣傳活動和支持政策也為市場成長做出了重大貢獻。然而，更有效的新藥物價格上漲限制了低收入國家的獲取，並直接影響市場成長。此外，具有廣泛抗藥性的結核分枝桿菌的演化是一個主要障礙，需要繼續研究和開發。此外，藥物開發和診斷技術的創新正在提高多重抗藥性結核病治療的有效性和可及性。

主要市場統計
基準年[2023] 2.81 億美元
預測年份 [2024] 31132萬美元
預測年份 [2030] 58862萬美元
複合年成長率（%） 11.14%

持續進行研究工作，支持開發治療耐多藥結核病的創新治療方法

多重抗藥性結核病治療包括多種抗生素，旨在治療至少對最強大的結核病藥物異煙肼和利福平具有抗藥性的結核分枝桿菌菌株。貝達喹啉給藥是多重抗藥性結核病治療的一個重要進步。貝達喹啉的作用是抑制結核分枝桿菌產生能量所需的一種酶，有效地將其餓死。德拉馬尼透過抑制分枝桿菌酸（細菌細胞壁的重要組成部分）的合成來針對分枝桿菌（導致結核病的細菌）。這種抑製作用可以殺死細菌。levofloxacin和莫西沙星屬於Fluoroquinolones藥物，是頻譜抗生素。levofloxacin和莫西沙星是頻譜抗生素，屬於Fluoroquinolones藥物。levofloxacin和莫西沙星透過抑制 DNA 旋轉酶和拓樸異構酶 IV 酶發揮作用，這些酶對於細菌 DNA 複製、轉錄、修復和重組非常重要，從而殺死細菌細胞。 Pretomanid 是治療結核病的新療法之一。 Pretomanid 通常用作包括貝達喹啉和Linezolid的三藥組合方案(BPaL) 的一部分，特別是用於治療廣泛抗藥性結核病。耐多藥結核病的治療不僅限於藥物治療，還包括支持性護理，以滿足患者的綜合健康需求。

分銷管道：提供密切醫療監測的線下分銷管道日益重要

醫院藥局是主要的線下管道之一。醫院藥房位於醫院內或醫院附近，直接向住院患者提供藥物，在許多情況下也向門診病人提供藥物。醫院藥局在需要密切醫療管理的多方面疾病（例如耐多藥結核病）中發揮著重要作用。透過提供立即獲得處方藥物的途徑來簡化治療過程。醫院藥劑師在為患者提供建議和管理藥物治療方案、確保充分滿足耐多藥結核病治療的複雜要求方面發揮著至關重要的作用。零售藥局獨立於醫院營運，更方便民眾使用。零售藥局位於社區內，提供患者取得處方藥物的便利地點。零售藥局滿足更廣泛的醫療保健需求，包括配發耐多藥結核病藥物。隨著數位技術的出現，線上藥局時代已經到來，並且作為耐多藥結核病治療藥物等的分銷管道正在不斷發展。該平台允許患者及其看護者透過網路訂購藥物，並將藥物直接送到家中。這種分發型態對於居住在偏遠地區或難以進入傳統藥房的患者尤其有利。網路藥局還具有更私密、更便利的優勢，有時可以獲得更廣泛的產品，並且可能有更優惠的價格。

區域洞察

美國和加拿大是美洲對抗多重抗藥性結核病的領先國家。與亞太地區和歐洲、中東和非洲地區相比，這些國家的發病率相對較低，凸顯了不同的挑戰和消費者需求。在美國，重點是在大量研究資金和專利申請的支持下，整合先進的診斷技術和開發新型療法，目標是將創新治療方法推向市場。歐盟國家應對耐多藥結核病的方法結合了先進的醫療基礎設施、強力的公共衛生政策和研究舉措。重點放在早期檢測、個人化醫療以及將新藥和新療法納入治療方案中。消費者行為的特徵是對醫療保健系統高度信任並願意參與疫苗接種和預防措施。中東面臨獨特的挑戰，包括報告品質參差不齊和醫療保健服務的可近性。人們正在大力加強醫療保健系統、提高診斷準確性並意識提升。中國、日本和印度是亞太地區多重抗藥性結核病（MDR-TB）高發生率國家。該地區的發病率很高，導致對有效治療藥物的大量需求。這些國家的消費者需求是由對可及、負擔得起和有效的治療方案的迫切需求所驅動的。

FPNV定位矩陣

FPNV定位矩陣對於評估多重抗藥性結核病藥物市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對耐多藥結核病治療藥物市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告對以下幾個方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4. 競爭評估和情報：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.多重抗藥性結核病治療市場的市場規模和預測是多少？

2.在多重抗藥性結核病治療藥物市場的預測期內，有哪些產品、細分市場、應用和領域需要考慮投資？

3.多重抗藥性結核病治療市場的技術趨勢和法規結構是什麼？

4.耐多藥結核病治療市場主要廠商的市場佔有率是多少？

5.進入耐多藥結核病藥物市場的適當型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地結核病病率上升
      • 越來越重視早期檢測和個人化醫療
      • 加強開發新藥的研發活動
    • 抑制因素
      • 耐多藥藥物的高成本且報銷選擇有限
    • 機會
      • 政府機構加強結核病宣導活動
      • 診斷程序的技術進步
    • 任務
      • 治療耐多藥結核病的複雜性
  • 市場區隔分析
    • 我們提供的服務：正在進行的研究工作，以加速開發治療耐多藥結核病的創新治療方法。
    • 分銷管道：線下分銷管道變得越來越重要，因為它們提供密切的醫療監測
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章 耐多藥結核病治療市場：透過提供

  • 藥品
  • 治療方法

第7章依管理方式分類的多重抗藥性結核病治療藥物市場

  • 注射藥物
  • 口腔醫學

第8章耐多藥結核病治療市場：依分銷管道分類

  • 離線
  • 線上

第9章 美洲耐多藥結核病治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太耐多藥結核病治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲耐多藥結核病藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 透過策略夥伴關係在全球擴大獲得突破性抗藥性結核病治療的機會
    • 全球抗擊多重抗藥性結核病的突破：貝達喹啉專利豁免，以改善低收入和中等收入國家的可及性
    • Aztreonam-阿維巴坦的臨床成功代表了對抗革蘭氏陰性菌感染疾病的突破
  • 戰略分析和建議

第13章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-7A22CB0E5A7D

[186 Pages Report] The Multidrug-resistant Tuberculosis Therapeutics Market size was estimated at USD 281.00 million in 2023 and expected to reach USD 311.32 million in 2024, at a CAGR 11.14% to reach USD 588.62 million by 2030.

Multidrug-resistant tuberculosis (MDR-TB) therapeutics refers to the treatment strategies and medications employed to combat tuberculosis (TB) strains that have developed resistance to at least the two most potent anti-tuberculosis drugs, isoniazid and rifampicin. These drugs are the cornerstone of standard tuberculosis treatment, and resistance to them complicates the treatment process significantly, necessitating the use of alternative medications. MDR-TB therapeutics typically involve a longer treatment duration, often lasting up to 24 months, and the use of second-line drugs, which can be more expensive, less effective, and carry a higher risk of side effects compared to the first-line drugs used for drug-sensitive TB. The rising incidences of tuberculosis, particularly in developing countries, directly correlate with heightened demand for effective MDR-TB treatments. Moreover, increased funding, awareness campaigns, and supportive policies from governments and non-government organizations worldwide have significantly contributed to market growth. However, the elevated cost of newer, more effective drugs limits access in low-income countries, directly impacting market growth. The evolution of extensively drug-resistant TB strains poses a substantial hurdle, necessitating continuous research and development efforts. Furthermore, innovations in drug development and diagnostic technologies have enhanced the efficacy and accessibility of MDR-TB treatments.

KEY MARKET STATISTICS
Base Year [2023] USD 281.00 million
Estimated Year [2024] USD 311.32 million
Forecast Year [2030] USD 588.62 million
CAGR (%) 11.14%

Offering: Ongoing research activities boosting the development of innovative therapies to treat multidrug-resistant tuberculosis

Medication for MDR-TB comprises various antibacterial drugs designed to treat TB strains resistant to at least isoniazid and rifampin, the two most potent tuberculosis drugs. Bedaquiline medication represents a significant advancement in the treatment of MDR-TB. Bedaquiline works by inhibiting an enzyme the TB bacteria require to generate energy, effectively starving and killing the bacteria. Delamanid targets the mycobacteria causing TB by inhibiting mycolic acid synthesis, a crucial component of the bacterial cell wall. This disruption leads to the death of the bacteria. Levofloxacin and Moxifloxacin drugs belong to a class called fluoroquinolones, which are broad-spectrum antibiotics. They have been found effective in treating TB strains that have become resistant to first-line anti-TB drugs. Levofloxacin and Moxifloxacin work by inhibiting the DNA gyrase and topoisomerase IV enzymes, which are crucial for replication, transcription, repair, and recombination of bacterial DNA, thereby leading to bacterial cell death. Pretomanid medication is one of the newer additions to the arsenal against TB. Pretomanid is typically used as part of a three-drug regimen (BPaL) that includes Bedaquiline and Linezolid, specifically for treating extensively drug-resistant TB. MDR-TB therapies extend beyond medication, incorporating supportive treatments that address the comprehensive health needs of patients.

Distribution Channel: Growing significance of offline distribution channel as it provide close medical supervision

Hospital pharmacies are one of the primary offline channels. These are located within or adjacent to a hospital, where they provide medications directly to the in-patients and, in many instances, to out-patients as well. For multifaceted diseases such as MDR-TB, which require close medical supervision, hospital pharmacies play a critical role. They ensure the immediate availability of prescribed therapeutics, streamlining the treatment process. Hospital pharmacists are pivotal in advising and managing the drug regimen for patients, ensuring that the intricate requirements of MDR-TB therapy are adequately met. Retail pharmacies operate independently of hospital settings and are more accessible to the general public. They are located within communities, serving as a convenient point for patients to access their prescribed medications. Retail pharmacies cater to a broader spectrum of healthcare needs, including the dispensation of MDR-TB drugs. The beginning of digital technology has ushered in the era of online pharmacies, a growing distribution channel for MDR-TB therapeutics, among others. This platform allows patients or their caregivers to order medications via the Internet, which are then delivered directly to their homes. This mode of distribution is particularly beneficial for patients residing in remote areas or those who have difficulty accessing traditional pharmacy outlets. Online pharmacies also offer the advantage of privacy, ease, and sometimes access to a wider range of products and potentially better pricing.

Regional Insights

The United States and Canada represent the Americas in the battle against MDR-TB. Though the incidence rates in these countries are relatively lower compared to the Asia Pacific and EMEA regions, they highlight a different set of challenges and consumer needs. In the United States, the focus is on the integration of advanced diagnostic techniques and the development of novel therapeutics backed by significant research funding and patent filings that aim to bring innovative treatments to the market. In the EU countries, the approach towards MDR-TB involves a combination of advanced healthcare infrastructure, robust public health policies, and research initiatives. The emphasis is on early detection, personalized medicine, and the integration of new drugs and regimens into treatment protocols. Consumer behavior is characterized by a high level of trust in the healthcare system and a willingness to participate in vaccination and preventive measures. The Middle East faces unique challenges, including variable reporting quality and access to healthcare services. Efforts are concentrated on strengthening healthcare systems, improving diagnostic accuracy, and increasing public awareness. China, Japan, and India are key countries in the Asia Pacific region significantly impacted by multidrug-resistant tuberculosis (MDR-TB). This region witnesses a high incidence rate, contributing to a considerable demand for effective therapeutics. Consumer needs in these countries are driven by the urgent necessity for accessible, affordable, and efficient treatment options.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Multidrug-resistant Tuberculosis Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Multidrug-resistant Tuberculosis Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Multidrug-resistant Tuberculosis Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abcam Limited, Daiichi Sankyo Co., Ltd., Endo International Plc, Johnson & Johnson Services Inc., Lupin Limited, Macleods Pharmaceuticals Ltd., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sanofi SA, and Santen Pharmaceutical Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Multidrug-resistant Tuberculosis Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Offering
    • Medication
      • Bedaquiline
      • Delamanid
      • Levofloxacin
      • Moxifloxacin
      • Pretomanid
    • Therapies
  • Mode of Administration
    • Injectable Medications
    • Oral Medications
  • Distribution Channel
    • Offline
      • Hospitals Pharmacies
      • Retail Pharmacies
    • Online
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Multidrug-resistant Tuberculosis Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Multidrug-resistant Tuberculosis Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Multidrug-resistant Tuberculosis Therapeutics Market?

4. What is the market share of the leading vendors in the Multidrug-resistant Tuberculosis Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Multidrug-resistant Tuberculosis Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of tuberculosis across the globe
      • 5.1.1.2. Growing emphasis is on early detection and personalized medicine
      • 5.1.1.3. Increasing research & development activities for new drug development
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of MDR drugs coupled with the limited reimbursement options
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing initiative from government organization for tuberculosis awareness
      • 5.1.3.2. Technological advancement in the diagnostics procedures
    • 5.1.4. Challenges
      • 5.1.4.1. Complexities associated with the treatment of multidrug-resistant tuberculosis
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Offering: Ongoing research activities boosting the development of innovative therapies to treat multidrug-resistant tuberculosis
    • 5.2.2. Distribution Channel: Growing significance of offline distribution channel as it provide close medical supervision
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Multidrug-resistant Tuberculosis Therapeutics Market, by Offering

  • 6.1. Introduction
  • 6.2. Medication
  • 6.3. Therapies

7. Multidrug-resistant Tuberculosis Therapeutics Market, by Mode of Administration

  • 7.1. Introduction
  • 7.2. Injectable Medications
  • 7.3. Oral Medications

8. Multidrug-resistant Tuberculosis Therapeutics Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Offline
  • 8.3. Online

9. Americas Multidrug-resistant Tuberculosis Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Multidrug-resistant Tuberculosis Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Multidrug-resistant Tuberculosis Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Expanding Global Access to Groundbreaking DR-TB Treatment Through Strategic Partnerships
    • 12.3.2. Breakthrough in Global Fight Against MDR TB: Bedaquiline Patents Waived to Enhance Access in Low- and Middle-Income Countries
    • 12.3.3. Breakthrough in Combating Gram-Negative Bacterial Infections with Aztreonam-Avibactam's Clinical Triumphs
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET DYNAMICS
  • FIGURE 7. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY BEDAQUILINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY BEDAQUILINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DELAMANID, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DELAMANID, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY LEVOFLOXACIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY LEVOFLOXACIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MOXIFLOXACIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MOXIFLOXACIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY PRETOMANID, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY PRETOMANID, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY INJECTABLE MEDICATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY INJECTABLE MEDICATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ORAL MEDICATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ORAL MEDICATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 44. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 45. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 46. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 51. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 52. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 55. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 56. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 57. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 58. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 59. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 60. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 61. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 62. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 63. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 64. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 65. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 66. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 67. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 68. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 69. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 70. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 71. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 72. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 73. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 74. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 75. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 76. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 77. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 78. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 79. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 80. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 81. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 82. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 83. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 84. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 85. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 86. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 87. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 88. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 89. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 90. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 91. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 92. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 93. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 94. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 95. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 96. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 97. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 98. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 99. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 100. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 101. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 102. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 103. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 104. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 105. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 106. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 120. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 122. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 124. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 126. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 128. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 129. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 130. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 131. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 132. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 133. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 134. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 135. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 136. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 137. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 138. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 139. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 140. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 141. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 142. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 143. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 144. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 145. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 146. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 147. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 148. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 149. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 150. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 151. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 152. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 153. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 154. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 155. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 156. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 157. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 158. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 159. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 160. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 161. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 162. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 163. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 164. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 165. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 166. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 167. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 168. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 169. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 170. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 171. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 172. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 173. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 174. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 175. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 176. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 177. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 178. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 179. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 180. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 181. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 182. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 183. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 184. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 186. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 188. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 189. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 190. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 191. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 192. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 193. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 194. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 195. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 196. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 197. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 198. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 199. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 200. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 201. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 202. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 203. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 204. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 206. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 207. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 208. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 209. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 210. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 211. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 212. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 213. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 214. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 215. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 216. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 217. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 218. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 219. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 220. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 221. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 222. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 223. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 224. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 225. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 226. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 227. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 228. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 229. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 230. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 231. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 232. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 233. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 234. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 235. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 236. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 237. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 238. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 251. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 252. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 253. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 254. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 255. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 256. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 257. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 258. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 259. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 260. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 261. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 262. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 263. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 264. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 265. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 266. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 267. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 268. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 269. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)

TABL